Personal

Ticket to Biotech

No refunds will be administered. Be sure that you're an accepted T2B member before paying for your ticket.

***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

If you're not part of Ticket to Biotech, 

, and join before registering for this event:

We're back in San Francisco in the middle of the year, this time with Mirum Pharmaceuticals hosting our community mixer at their office.

This come-and-go networking event is open to all biopharma communicators in the T2B community. Complimentary snacks and drinks will be provided.

​We are also partnering with Life Science Cares for a community giveback activity.

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities.

The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at 

At Life Science Cares, we believe the same innovation that transforms health outcomes can also transform communities. Working as a bridge between the life science industry and committed community organizations, we’re building a movement of service that meets real needs in the cities we work in. Learn more at 

Q2 T2Bmeet @ SF 2026